Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL Inc. has experienced a substantial share price increase of nearly 90% over the past month, indicating strong market interest and confidence in the company’s prospects. Recent data from the PATHFINDER 2 ESMO trial has enhanced optimism regarding the upcoming NHS Galleri trial results, while proprietary total addressable market (TAM) analysis suggests significant growth potential in the US and UK, estimated at approximately $3.7 billion by 2026 and $4.0 billion by 2035. Additionally, the establishment of strategic partnerships to tap into this market opportunity further solidifies GRAIL's competitive advantage in the multi-cancer early detection space, despite ongoing uncertainties surrounding regulatory approvals and reimbursement issues.

Bears say

GRAIL Inc has faced substantial net losses since its inception and expects these losses to persist as it continues with clinical studies and seeks regulatory approvals, highlighting a significant financial risk. The company faces numerous challenges, including potential delays in reimbursement pathways for its multi-cancer early detection (MCED) tests and heightened competition from established diagnostic firms, which could hinder its market penetration. Additionally, increased selling, general, and administrative (SG&A) expenses could further strain GRAIL's financial resources, particularly if the company's efforts to expand commercialization of its Galleri test do not yield the expected results.

GRAIL Inc (GRAL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 4 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.